DK1311279T3 - Behandling af hepatitis C med thymosin, interferon og ribavirin - Google Patents

Behandling af hepatitis C med thymosin, interferon og ribavirin

Info

Publication number: DK1311279T3
Authority: DK; Denmark
Prior art keywords: hepatitis; thymosin; interferon; ribavirin; treatment
Prior art date: 2000-08-07

Application number

DK01962344T

Other languages

English (en)

Inventor

Alfred R Rudolph

Original Assignee

Sciclone Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-07

Filing date

2001-08-06

Publication date

2007-02-12

2001-08-06 Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc

2007-02-12 Application granted granted Critical

2007-02-12 Publication of DK1311279T3 publication Critical patent/DK1311279T3/da

Links

208000005176 Hepatitis C Diseases 0.000 title abstract 4
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title abstract 3
102000014150 Interferons Human genes 0.000 title abstract 2
108010050904 Interferons Proteins 0.000 title abstract 2
102000007501 Thymosin Human genes 0.000 title abstract 2
108010046075 Thymosin Proteins 0.000 title abstract 2
229940079322 interferon Drugs 0.000 title abstract 2
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title 1
229960000329 ribavirin Drugs 0.000 title 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title 1
239000003443 antiviral agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK01962344T 2000-08-07 2001-08-06 Behandling af hepatitis C med thymosin, interferon og ribavirin DK1311279T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22331700P	2000-08-07	2000-08-07
PCT/US2001/041550 WO2002011749A1 (en)	2000-08-07	2001-08-06	Treatment of hepatitis c with thymosin, interferon and ribavirin

Publications (1)

Publication Number	Publication Date
DK1311279T3 true DK1311279T3 (da)	2007-02-12

Family

ID=22835988

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01962344T DK1311279T3 (da)	2000-08-07	2001-08-06	Behandling af hepatitis C med thymosin, interferon og ribavirin

Country Status (17)

Country	Link
EP (1)	EP1311279B1 (da)
KR (1)	KR100851861B1 (da)
CN (1)	CN1446096A (da)
AT (1)	ATE348628T1 (da)
AU (2)	AU8353601A (da)
BR (1)	BR0113115A (da)
CA (1)	CA2418085A1 (da)
CY (1)	CY1106388T1 (da)
DE (1)	DE60125377T2 (da)
DK (1)	DK1311279T3 (da)
EA (1)	EA007785B1 (da)
ES (1)	ES2275711T3 (da)
IL (1)	IL154299A0 (da)
MX (1)	MXPA03001145A (da)
NZ (1)	NZ524579A (da)
PT (1)	PT1311279E (da)
WO (1)	WO2002011749A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2011530519A (ja) *	2008-08-06	2011-12-22	サイクローン・ファーマシューティカルズ・インコーポレイテッド	免疫調節化合物を用いたｃ型肝炎の治療または予防の方法
JP2012526149A (ja)	2009-05-08	2012-10-25	サイクローン・ファーマシューティカルズ・インコーポレイテッド	ワクチン増強剤としてのαチモシンペプチド
RU2473341C1 (ru) *	2011-08-02	2013-01-27	Государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО СибГМУ Минздравсоцразвития)	Способ профилактики вертикальной передачи вирусов гепатитов в и с у беременных с реактивацией вирусов в третьем триместре

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW224053B (da) *	1991-09-13	1994-05-21	Paul B Chretien
US5610054A (en) *	1992-05-14	1997-03-11	Ribozyme Pharmaceuticals, Inc.	Enzymatic RNA molecule targeted against Hepatitis C virus
US5849800A (en) *	1997-03-28	1998-12-15	The Penn State Research Foundation	Use of amantadine for treatment of Hepatitis C
JP3839667B2 (ja) *	1998-06-08	2006-11-01	エフ．ホフマン−ラロシュアーゲー	慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
CA2354536A1 (en) *	1998-12-18	2000-06-29	Schering Corporation	Ribavirin-pegylated interferon alfa induction hcv combination therapy

2001
- 2001-08-06 AU AU8353601A patent/AU8353601A/xx active Pending
- 2001-08-06 CA CA002418085A patent/CA2418085A1/en not_active Abandoned
- 2001-08-06 WO PCT/US2001/041550 patent/WO2002011749A1/en not_active Ceased
- 2001-08-06 AT AT01962344T patent/ATE348628T1/de active
- 2001-08-06 CN CN01813766A patent/CN1446096A/zh active Pending
- 2001-08-06 ES ES01962344T patent/ES2275711T3/es not_active Expired - Lifetime
- 2001-08-06 BR BR0113115-0A patent/BR0113115A/pt not_active IP Right Cessation
- 2001-08-06 DE DE60125377T patent/DE60125377T2/de not_active Expired - Lifetime
- 2001-08-06 KR KR1020037001718A patent/KR100851861B1/ko not_active Expired - Fee Related
- 2001-08-06 PT PT01962344T patent/PT1311279E/pt unknown
- 2001-08-06 DK DK01962344T patent/DK1311279T3/da active
- 2001-08-06 IL IL15429901A patent/IL154299A0/xx unknown
- 2001-08-06 AU AU2001283536A patent/AU2001283536B2/en not_active Ceased
- 2001-08-06 EA EA200300222A patent/EA007785B1/ru not_active IP Right Cessation
- 2001-08-06 NZ NZ524579A patent/NZ524579A/en unknown
- 2001-08-06 EP EP01962344A patent/EP1311279B1/en not_active Expired - Lifetime
- 2001-08-06 MX MXPA03001145A patent/MXPA03001145A/es active IP Right Grant
2007
- 2007-03-15 CY CY20071100368T patent/CY1106388T1/el unknown

Also Published As

Publication number	Publication date
BR0113115A (pt)	2003-06-10
AU8353601A (en)	2002-02-18
AU2001283536B2 (en)	2005-09-01
WO2002011749A1 (en)	2002-02-14
EA200300222A1 (ru)	2003-08-28
DE60125377D1 (de)	2007-02-01
CY1106388T1 (el)	2011-10-12
EP1311279A1 (en)	2003-05-21
CA2418085A1 (en)	2002-02-14
ES2275711T3 (es)	2007-06-16
NZ524579A (en)	2004-06-25
PT1311279E (pt)	2007-03-30
ATE348628T1 (de)	2007-01-15
EP1311279B1 (en)	2006-12-20
IL154299A0 (en)	2003-09-17
HK1055689A1 (en)	2004-01-21
DE60125377T2 (de)	2007-09-27
EA007785B1 (ru)	2007-02-27
EP1311279A4 (en)	2004-08-11
KR20030034129A (ko)	2003-05-01
MXPA03001145A (es)	2004-08-02
KR100851861B1 (ko)	2008-08-13
CN1446096A (zh)	2003-10-01

Publication	Publication Date	Title
AR021876A1 (es)	2002-08-07	Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
MY124091A (en)	2006-06-30	Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
RS20120201A3 (en)	2013-06-28	Methods and compositions for hepatitis c virus treatment
DK1658302T3 (da)	2010-11-22	Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
AR023541A1 (es)	2002-09-04	Terapia de combinacion para vhc
PT956861E (pt)	2002-08-30	Terapia combinada compreendendo ribavirina e interferao alfa em doentes sem tratamento antiviral anterior tendo infeccao cronica pelo virus da hepatite c
PL1778272T3 (pl)	2011-07-29	Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV)
DE60237721D1 (de)	2010-10-28	Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
AR022116A1 (es)	2002-09-04	Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
DK1115420T3 (da)	2002-11-04	Behandling af hepatitis B med thymosin-alpha-1 og lamivudin
AR036697A1 (es)	2004-09-29	Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
CY1106388T1 (el)	2011-10-12	Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη
DK1311286T3 (da)	2006-10-30	Behandling af hepatitis C med thymosin og pegyleret interferon
AR036698A1 (es)	2004-09-29	Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
TR200000728T2 (tr)	2000-09-21	Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
ECSP993003A (es)	2000-01-27	Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica
RU99125410A (ru)	2001-08-27	Способ лечения хронических вирусных гепатитов
ECSP003446A (es)	2000-11-24	Terapia de combinacion para vhc
TH53874A (th)	2002-11-18	การบำบัดรักษา hcv แบบผสมผสานโดยการเหนี่ยวนำด้วยไรบาไวรินและอินเทอฟีรอนอัลฟาชนิดเพกิเลเตด